Recruiting
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
ClinicalTrials.gov IDNCT04354545
PhaseNot Applicable
Enrollment75
SponsorUniversity of California, Los Angeles
AgeNo minimum reported
SexALL
Conditions studied
Glaucoma, Ocular Surface Disease
About this study
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
Interventions
- Drug: Xiidra (Lifitegrast ophthalmic solution) 5% — FDA approved lifitegrast opthalmic solution eye drop
Primary outcomes
- Change from baseline to week 12 in corneal fluorescein staining score (From baseline to Week 12)
- Change from baseline to week 12 in eye dryness score (EDS) (From baseline to Week 12)
- Change from baseline to week 12 in ocular surface disease index (OSDI) questionnaire score (From baseline to Week 12)
Eligibility information
Inclusion Criteria:
* Currently using one or more topical glaucoma antihypertensives
* Self-described symptoms of ocular surface discomfort
* Xiidra is being prescribed as part of the subject's standard care
Exclusion Criteria:
* History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
* current use of topical cyclosporine
* current use of topical steroids
* incisional ocular surgery within 6 months
Study locations
- Doheny Eye Center UCLA, Fountain Valley, California 92708 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.